目的 观察天丹通络片联合尤瑞克林对急性脑梗死患者治疗效果、神经功能等指标的影响，以期为临床疾病治疗提供参考依据。方法 纳入2023年2月—2025年2月临汾市人民医院收治的130例急性脑梗死患者，依据治疗方式的差异将患者分成对照组和治疗组，各65例。对照组静脉滴注注射用尤瑞克林，0.15 PNA单位溶于0.9%氯化钠注射液100 mL，静脉滴注30 min，1次/d。治疗组在对照组基础上口服天丹通络片，5片/次，3次/d。两组均治疗3周。观察两组临床疗效，对比美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数（BI）、白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、白细胞介素-10（IL-10）、血清神经元特异性烯醇化酶（NSE）、同型半胱氨酸（Hcy）、S100钙结合蛋白β（S100β），胶质纤维酸性蛋白（GFAP）的变化情况。结果 治疗后，治疗组总有效率是90.77%，较对照组的72.31%显著提高（P＜0.05）。治疗结束时，两组NIHSS均降低，BI升高，且治疗组NIHSS低于对照组，BI高于对照组（P＜0.05）。治疗后，两组hs-CRP、IL-6较同组治疗前显著降低，而IL-10升高（P＜0.05）；治疗结束，治疗组hs-CRP、IL-6均低于对照组，而IL-10高于对照组（P＜0.05）。治疗后，两组NSE、Hcy、S100β、GFAP均较同组治疗前显著降低（P＜0.05）；且治疗后，治疗组NSE、Hcy、S100β、GFAP低于对照组（P＜0.05）。结论 天丹通络片联合注射用尤瑞克林利于提高急性脑梗死的临床疗效，促进神经功能与日常生活活动能力恢复，改善炎症状态，且安全性尚可。

Objective To observe the effect of Tiandan Tongluo Tablets combined with uricillin on the therapeutic effect, neurological function and other indicators of patients with acute cerebral infarction, in order to provide a reference basis for clinical disease treatment. Methods A total of 130 patients with acute cerebral infarction admitted to Linfen People’s Hospital from February 2023 to February 2025 were included. According to differences in treatment methods, the patients were divided into control group and treatment group, with 65 cases in each group. Patients in control group were intravenously infused with Urinary Kallidinogenase for injection, 0.15 PNA units were dissolved in 100 mL of 0.9% sodium chloride injection and intravenously infused for 30 min, once daily. Patients in treatment group took Tiandan Tongluo Tablets orally on the basis of control group, 5 tablets each time, 3 times daily. Both groups were treated for 3 weeks. The clinical efficacy of two groups was observed, and changes of NIHSS scores, BI, IL-6, hs-CRP, IL-10, NSE, Hcy, S100β, and GFAP in two groups were compared. Results After treatment, the total effective rate of treatment group was 90.77%, which was significantly higher than that of control group 72.31% (P < 0.05). At the end of the treatment, NIHSS decreased and BI increased in both groups. Moreover, NIHSS in treatment group was lower than that in control group, while BI was higher than that in control group (P < 0.05). After treatment, the levels of hs-CRP and IL-6 in both groups were significantly lower than those before treatment in the same group, while IL-10 increased (P < 0.05). At the end of the treatment, the levels of hs-CRP and IL-6 in treatment group were lower than those in control group, while IL-10 was higher than that in control group (P < 0.05). After treatment, NSE, Hcy, S100β, and GFAP in both groups were significantly lower than those before treatment in the same group (P < 0.05). Moreover, after the treatment, the NSE, Hcy, S100β, and GFAP in treatment group were lower than those in control group (P< 0.05). Conclusion The combination of Tiandan Tongluo Tablets and uricillin for injection is beneficial to improving the clinical efficacy of acute cerebral infarction, promoting the recovery of neurological function and activities of daily living, improving the inflammatory state, and the safety is acceptable.

R971

山西省高等学校科技创新计划项目（2024L131）